Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis
20 Novembre 2023
Chiesi Group Partnership Day 2023
16 Novembre 2023
Chiesi Global Rare Diseases Releases Report on the Burden of Care for Rare Diseases and Its Economic Impact on European Citizens
30 Ottobre 2023
Chiesi Foundation’s NEST Partners Meeting in Sub-Saharan Africa
27 Ottobre 2023
Chiesi Global Rare Diseases Announces Multiple Presentations at SSIEM Annual Symposium 2023
01 Settembre 2023
Climate Change Threatens Respiratory Patients' Quality of Life Stretching Beyond Physical Health to Overall Well-Being, New Report Warns
07 Settembre 2023
Chiesi Group mid-year financial results demonstrate strong growth for 2023
03 Agosto 2023
Chiesi's Sustainability Report 2022: a year of tangible achievements for patients, communities, and the planet
27 Luglio 2023
Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
07 Luglio 2023
Chiesi at EPNS 2023 to confirm its commitment on alpha-mannosidosis with the projection of the movie “Rare Land” and the presentation of 4 posters
